Swiss pharma firm Sandoz invests $440 million in Slovenia

Sandoz is expanding its presence in Slovenia. The Basel-based generics giant has launched the construction of a new biosimilars production centre in Brnik at a cost of $440 million (CHF349 million). +Get the most important news from Switzerland in your inbox The announcement brings current and planned investments in the small Alpine country to more than $1.1 billion by 2029, according to a press release issued on Tuesday by the specialist in generic and biosimilar treatments. These include a new biosimilars production centre in Lendava and a development centre in the capital, Ljubljana. Sandoz intends to take advantage of an “unprecedented market opportunity”, with patent expiries expected to reach $222 billion over the next ten years. The Group believes it is the leading foreign direct investor in the European country. Translated from German by DeepL/jdp How we work We select the most relevant news for an international audience and use automatic translation tools to translate them ... Full story here Are you the author? Previous post See more for 3.) Swissinfo Business and Economy Next post
Tags: Featured,newsletter